APA (7th ed.) Citation

Ralph, C., Gupta, S., Zibelman, M., Curti, B. D., Harrington, K. J., O'Day, S. J., . . . Guttman, L. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Ralph, Christy, et al. Phase 1, Open-label, Dose-escalation Study on the Safety, Pharmacokinetics, and Preliminary Efficacy of Intravenous Coxsackievirus A21 (V937), with or Without Pembrolizumab, in Patients with Advanced Solid Tumors. BMJ Publishing Group.

MLA (9th ed.) Citation

Ralph, Christy, et al. Phase 1, Open-label, Dose-escalation Study on the Safety, Pharmacokinetics, and Preliminary Efficacy of Intravenous Coxsackievirus A21 (V937), with or Without Pembrolizumab, in Patients with Advanced Solid Tumors. BMJ Publishing Group.